TY - JOUR
T1 - Mitral regurgitation after myocardial infarction
T2 - A review
AU - Bursi, Francesca
AU - Enriquez-Sarano, Maurice
AU - Jacobsen, Steven J.
AU - Roger, Véronique L.
N1 - Funding Information:
Grant Support: By the Public Health Service and the National Institutes of Health (AR30582, R01 HL 59205, R01 HL 72435) and by an American Heart Association Greater Midwest Postdoctoral Fellowship Award to Dr Bursi. Dr Roger is an Established Investigator of the American Heart Association.
PY - 2006/2
Y1 - 2006/2
N2 - Mitral regurgitation after myocardial infarction is the result of multifactorial processes involving local and global left ventricular remodeling. The prevalence of mitral regurgitation varies from 11% to 59%. Published studies differ greatly in design, inclusion criteria, duration of follow-up, and technique of mitral regurgitation assessment. However, they consistently indicate that mitral regurgitation after myocardial infarction carries an adverse prognosis with increased risk of death and heart failure independently of previously known indicators of risk after myocardial infarction. Mitral regurgitation is often clinically silent; therefore, it should be systematically evaluated by echocardiography. Standard color Doppler imaging is a highly sensitive method to detect even mild degrees of ischemic mitral regurgitation. One unique advantage of echocardiography is that it accurately quantifies the severity of mitral regurgitation by measuring the effective regurgitant orifice area and the regurgitant volume using Doppler methodology. Therefore, the evaluation should include precise quantification of the degree of mitral regurgitation to best appraise the ensuing risk. Current medical options rely chiefly on angiotensin converting enzyme-inhibitors and beta-blocker therapy, and surgical approaches offer future promise. Both categories of therapeutic approaches should be evaluated by randomized controlled trials.
AB - Mitral regurgitation after myocardial infarction is the result of multifactorial processes involving local and global left ventricular remodeling. The prevalence of mitral regurgitation varies from 11% to 59%. Published studies differ greatly in design, inclusion criteria, duration of follow-up, and technique of mitral regurgitation assessment. However, they consistently indicate that mitral regurgitation after myocardial infarction carries an adverse prognosis with increased risk of death and heart failure independently of previously known indicators of risk after myocardial infarction. Mitral regurgitation is often clinically silent; therefore, it should be systematically evaluated by echocardiography. Standard color Doppler imaging is a highly sensitive method to detect even mild degrees of ischemic mitral regurgitation. One unique advantage of echocardiography is that it accurately quantifies the severity of mitral regurgitation by measuring the effective regurgitant orifice area and the regurgitant volume using Doppler methodology. Therefore, the evaluation should include precise quantification of the degree of mitral regurgitation to best appraise the ensuing risk. Current medical options rely chiefly on angiotensin converting enzyme-inhibitors and beta-blocker therapy, and surgical approaches offer future promise. Both categories of therapeutic approaches should be evaluated by randomized controlled trials.
KW - Mechanism
KW - Mitral regurgitation
KW - Myocardial infarction
KW - Prevalence
KW - Prognosis
UR - http://www.scopus.com/inward/record.url?scp=31444456955&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=31444456955&partnerID=8YFLogxK
U2 - 10.1016/j.amjmed.2005.08.025
DO - 10.1016/j.amjmed.2005.08.025
M3 - Review article
C2 - 16443408
AN - SCOPUS:31444456955
SN - 0002-9343
VL - 119
SP - 103
EP - 112
JO - American Journal of Medicine
JF - American Journal of Medicine
IS - 2
ER -